X
40.05
0.60 (1.52%)
| Previous Close | 39.45 |
| Open | 39.02 |
| Volume | 418,485 |
| Avg. Volume (3M) | 369,459 |
| Market Cap | 3,053,395,968 |
| Price / Book | 3.72 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Diluted EPS (TTM) | -2.81 |
| Total Debt/Equity (MRQ) | 1.19% |
| Current Ratio (MRQ) | 23.27 |
| Operating Cash Flow (TTM) | -153.55 M |
| Levered Free Cash Flow (TTM) | -104.09 M |
| Return on Assets (TTM) | -18.92% |
| Return on Equity (TTM) | -26.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Xenon Pharmaceuticals Inc. | Bearish | Bearish |
AIStockmoo Score
0.0
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 0.38% |
| % Held by Institutions | 101.18% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (Needham, 49.81%) | Buy |
| Median | 53.00 (32.34%) | |
| Low | 50.00 (Raymond James, 24.84%) | Buy |
| Average | 54.33 (35.66%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 40.61 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Dec 2024 | 53.00 (32.33%) | Buy | 39.45 |
| 13 Nov 2024 | 53.00 (32.33%) | Buy | 41.97 | |
| Needham | 13 Nov 2024 | 60.00 (49.81%) | Buy | 41.97 |
| Raymond James | 10 Oct 2024 | 50.00 (24.84%) | Buy | 40.41 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AULIN SHERRY | - | 39.35 | -25,334 | -996,893 |
| Aggregate Net Quantity | -25,334 | |||
| Aggregate Net Value ($) | -996,893 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 39.35 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AULIN SHERRY | Officer | 18 Dec 2024 | Disposed (-) | 6,625 | 39.35 | 260,694 |
| AULIN SHERRY | Officer | 18 Dec 2024 | Sell (-) | 18,709 | 39.35 | 736,199 |
| AULIN SHERRY | Officer | 18 Dec 2024 | Option execute | 25,334 | - | - |
| Date | Type | Details |
|---|---|---|
| 06 Dec 2024 | Announcement | Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 |
| 25 Nov 2024 | Announcement | Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 |
| 13 Nov 2024 | Announcement | Xenon to Present at Upcoming Investor Conferences |
| 12 Nov 2024 | Announcement | Xenon Reports Q3 2024 Financial Results and Business Update |
| 05 Nov 2024 | Announcement | Xenon to Report Q3 2024 Financial Results on November 12, 2024 |
| 02 Oct 2024 | Announcement | Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |